

Ref: FOI/GS/ID 7537

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

11 July 2022

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis and hidradenitis suppurativa treatments.

You asked:

1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

2) Of these five, how many of each received the following products:

- a. Adalimumab (Humira)*
- b. Adalimumab Biosimilar*
- c. Etanercept (Enbrel)*
- d. Etanercept Biosimilar*
- e. Infliximab (Remicade)*
- f. Infliximab biosimilar*
- g. Golimumab (Simponi)*
- h. Tofacitinib (Xeljanz)*
- i. Ustekinumab (Stelara)*
- j. Vedolizumab (Entyvio)*
- k. Filgotinib (Jyseleca)*
- l. Abatacept (Orencia)*
- m. Baricitinib (Olumiant)*
- n. Certolizumab Pegol (Cimzia)*
- o. Rituximab (MabThera)*
- p. Rituximab Biosimilar*
- q. Tocilizumab (RoActemra)*
- r. Sarilumab (Kevzara)*
- s. Apremilast (Otezla)*

- t. Secukinumab (Cosentyx)
- u. Isekizumab (Taltz)
- v. Guselkumab (Tremfya)
- w. Brodalumab (Kyntheum)
- x. Risankizumab (Skyrizi)
- y. Tildrakizumab (Ilumetri)
- z. Upadacitinib (Rinvoq)
- aa. Bimekizumab (Bimzelx)

3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- a. AxSPA
- b. PsA
- c. PsO

Trust response:

Under Section 21 of the Act we are not required to provide information in response to a request if the information is already reasonably accessible to you. The information you requested is available from the trust website using the following link/s: <https://www.mtw.nhs.uk/freedom-of-information/recent-foiresponses/> the link should take you to the Data to Support FOI FAQ's page where you need to click on the Pharmacy dropdown.

The information can be found on the April 2021-March 2022 Rheumatology and Gastroenterology drugs indication by quarter.xlsx report.

Alternatively, from our website home page, click the Freedom of Information Tab, then the Data to Support FOI FAQ's tab and then the Pharmacy dropdown at the bottom of the page where you will find all the information.

This information is updated on a regular basis and is exempt under Section 22 of the Act.